Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai
  • Diabetes Obesity and Metabolism, January 2018, Wiley
  • DOI: 10.1111/dom.13170
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Kohei Kaku

In partnership with: